Open AccessProspective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making
Author(s) -
Wassim Abida,
Joshua Armenia,
Anuradha Gopalan,
Ryan Brennan,
Michael F. Walsh,
David Barron,
Daniel C. Danila,
Dana E. Rathkopf,
Michael J. Morris,
Susan F. Slovin,
Brigit McLaughlin,
Kristen Curtis,
David M. Hyman,
Jeremy C. Durack,
Stephen B. Solomon,
Maria E. Arcila,
Ahmet Zehir,
Aijazuddin Syed,
Jianjiong Gao,
Debyani Chakravarty,
Hebert Alberto Vargas,
Mark E. Robson,
Joseph Vijai,
Kenneth Offit,
Mark T.A. Donoghue,
Adam Abeshouse,
Ritika Kundra,
Zachary J. Heins,
A. Penson,
Christopher Harris,
Barry S. Taylor,
Marc Ladanyi,
Diana Mandelker,
Liying Zhang,
Victor E. Reuter,
Philip W. Kantoff,
David B. Solit,
Michael F. Berger,
Charles L. Sawyers,
Nikolaus Schultz,
Howard I. Scher
Publication year - 2017
Publication title -
jco precision oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.405
H-Index - 22
ISSN - 2473-4284
DOI - 10.1200/po.17.00029
Subject(s) - prostate cancer , germline , somatic cell , metastasis , disease , germline mutation , prostate , cancer research , cancer , biology , medicine , oncology , gene , genetics , mutation
A long natural history and a predominant osseous pattern of metastatic spread are impediments to the adoption of precision medicine in patients with prostate cancer. To establish the feasibility of clinical genomic profiling in the disease, we performed targeted deep sequencing of tumor and normal DNA from patients with locoregional, metastatic non-castrate, and metastatic castration-resistant prostate cancer (CRPC).